Do analysts rate NCNA or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NCNA or TXMD more profitable?

TherapeuticsMD has a net margin of 5.34% compared to NuCana's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% TherapeuticsMD 5.34% 0.32% 0.23%

Do analysts rate KZIA or NCNA?

Novogen currently has a consensus price target of $25.80, suggesting a potential upside of 85.28%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, KZIA or NCNA?

Novogen has higher revenue and earnings than NuCana. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 765.88 -$13.41M N/A N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is KZIA or NCNA more profitable?

Novogen's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A NuCana N/A -153.61% -116.03%

Do analysts prefer SKYE or NCNA?

Skye Bioscience currently has a consensus price target of $8.50, indicating a potential upside of 1,207.69%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Skye Bioscience is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SKYE or NCNA?

Skye Bioscience is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is SKYE or NCNA more profitable?

NuCana's return on equity of -153.61% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% NuCana N/A -153.61% -116.03%

Do analysts rate ATOS or NCNA?

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 689.95%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ATOS or NCNA?

Atossa Genetics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is ATOS or NCNA more profitable?

Atossa Genetics' return on equity of -84.91% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% NuCana N/A -153.61% -116.03%

Do analysts recommend NCNA or NCEL?

NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 505.26%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, NCNA or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$2.98 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is NCNA or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% NLS Pharmaceutics N/A N/A N/A

NuCana (NCNA) Competitors

$1.33 +0.02 (+1.37%)

As of 10:38 AM Eastern

Compare

NCNA vs. TXMD, KZIA, SKYE, ATOS, and NCEL

Should you buy NuCana stock or one of its competitors? MarketBeat compares NuCana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NuCana include TherapeuticsMD (TXMD), Novogen (KZIA), Skye Bioscience (SKYE), Atossa Genetics (ATOS), and NLS Pharmaceutics (NCEL). These companies are all part of the "pharmaceutical products" industry.

How does NuCana compare to TherapeuticsMD?

NuCana (NASDAQ:NCNA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

44.0% of NuCana shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of 5.34% compared to NuCana's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
TherapeuticsMD	5.34%	0.32%	0.23%

TherapeuticsMD has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33

In the previous week, NuCana's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
TherapeuticsMD	Neutral

NuCana has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

TherapeuticsMD beats NuCana on 7 of the 10 factors compared between the two stocks.

How does NuCana compare to Novogen?

Novogen (NASDAQ:KZIA) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Novogen currently has a consensus price target of $25.80, suggesting a potential upside of 85.28%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.9% of Novogen shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Novogen had 2 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Novogen and 0 mentions for NuCana. Novogen's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
NuCana	Neutral

Novogen's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
NuCana	N/A	-153.61%	-116.03%

Novogen has higher revenue and earnings than NuCana.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	765.88	-$13.41M	N/A	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, NuCana has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Summary

Novogen beats NuCana on 8 of the 11 factors compared between the two stocks.

How does NuCana compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Skye Bioscience currently has a consensus price target of $8.50, indicating a potential upside of 1,207.69%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Skye Bioscience is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Skye Bioscience has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market. Comparatively, NuCana has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Skye Bioscience is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

NuCana's return on equity of -153.61% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
NuCana	N/A	-153.61%	-116.03%

In the previous week, Skye Bioscience's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
NuCana	Neutral

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Skye Bioscience and NuCana tied by winning 6 of the 12 factors compared between the two stocks.

How does NuCana compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, Atossa Genetics had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for NuCana. Atossa Genetics' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Atossa Genetics	Neutral
NuCana	Neutral

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, NuCana has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Atossa Genetics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 689.95%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atossa Genetics' return on equity of -84.91% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
NuCana	N/A	-153.61%	-116.03%

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Atossa Genetics beats NuCana on 7 of the 12 factors compared between the two stocks.

How does NuCana compare to NLS Pharmaceutics?

NuCana (NASDAQ:NCNA) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 505.26%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

44.0% of NuCana shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NuCana has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

NLS Pharmaceutics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
NLS Pharmaceutics	N/A	N/A	N/A

In the previous week, NLS Pharmaceutics' average media sentiment score of 1.00 beat NuCana's score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NuCana	Neutral
NLS Pharmaceutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Summary

NLS Pharmaceutics beats NuCana on 7 of the 10 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.50M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.44	20.71	27.09	24.07
Price / Sales	N/A	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.17	7.99	10.64	6.20
Net Income	-$38.71M	$23.81M	$3.60B	$331.63M
7 Day Performance	1.37%	-1.92%	-1.41%	-1.54%
1 Month Performance	-30.47%	1.88%	0.97%	-1.17%
1 Year Performance	-86.98%	43.58%	24.23%	17.81%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	0.8336 of 5 stars	$1.33 +1.4%	N/A	-86.3%	$5.50M	N/A	N/A	30
TXMD TherapeuticsMD	0.6556 of 5 stars	$2.04 +5.2%	N/A	+83.5%	$22.45M	$3.02M	34.00	420	Positive News Gap Down
KZIA Novogen	1.3683 of 5 stars	$13.12 -2.4%	$25.80 +96.6%	+33.5%	$22.22M	$30K	N/A	12	Gap Up
SKYE Skye Bioscience	1.6116 of 5 stars	$0.63 +3.7%	$8.50 +1,252.2%	-83.2%	$21.30M	N/A	N/A	11
ATOS Atossa Genetics	2.0329 of 5 stars	$2.39 -2.0%	$20.33 +750.8%	-80.3%	$21.01M	N/A	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. TXMD, KZIA, SKYE, ATOS, and NCEL

How does NuCana compare to TherapeuticsMD?

Summary

How does NuCana compare to Novogen?

Summary

How does NuCana compare to Skye Bioscience?

Summary

How does NuCana compare to Atossa Genetics?

Summary

How does NuCana compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. TXMD, KZIA, SKYE, ATOS, and NCEL

How does NuCana compare to TherapeuticsMD?

Do insiders and institutionals have more ownership in NCNA or TXMD?

Do analysts rate NCNA or TXMD?

Is NCNA or TXMD more profitable?

Which has preferable valuation & earnings, NCNA or TXMD?

Does the media favor NCNA or TXMD?

Which has more risk & volatility, NCNA or TXMD?

Summary

How does NuCana compare to Novogen?

Do analysts rate KZIA or NCNA?

Do insiders and institutionals have more ownership in KZIA or NCNA?

Does the media refer more to KZIA or NCNA?

Is KZIA or NCNA more profitable?

Which has higher earnings & valuation, KZIA or NCNA?

Which has more risk & volatility, KZIA or NCNA?

Summary

How does NuCana compare to Skye Bioscience?

Do analysts prefer SKYE or NCNA?

Which has more volatility & risk, SKYE or NCNA?

Which has better earnings & valuation, SKYE or NCNA?

Is SKYE or NCNA more profitable?

Does the media refer more to SKYE or NCNA?

Do insiders & institutionals have more ownership in SKYE or NCNA?

Summary

How does NuCana compare to Atossa Genetics?

Does the media refer more to ATOS or NCNA?

Which has more volatility & risk, ATOS or NCNA?

Which has preferable valuation and earnings, ATOS or NCNA?

Do analysts rate ATOS or NCNA?

Is ATOS or NCNA more profitable?

Do insiders and institutionals believe in ATOS or NCNA?

Summary

How does NuCana compare to NLS Pharmaceutics?

Do analysts recommend NCNA or NCEL?

Do institutionals & insiders hold more shares of NCNA or NCEL?

Which has more volatility & risk, NCNA or NCEL?

Is NCNA or NCEL more profitable?

Does the media prefer NCNA or NCEL?

Which has better valuation and earnings, NCNA or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools